A study published in JAMA Network Open demonstrates that men who have low levels of prostate-specific antigen (PSA) have a markedly reduced risk of developing prostate cancer within the following 20 years. Specifically, among men aged 45 to 70 whose PSA levels were below 1.00 µg/l, only 3% developed prostate cancer after a two-decade follow-up. This contrasts sharply with data indicating that nearly 35% of men with PSA levels exceeding 3 µg/l faced a much higher risk of the disease.

The research involved 2,700 German men who were free of prostate cancer at the start of a 20-year observation period. Participants underwent a single PSA test, and results indicate that in addition to low PSA levels, older age and PSA density, which is the ratio of PSA to prostate volume, also contributed to higher prostate cancer risk. The study highlights the importance of PSA testing in identifying men who may not require further invasive screening procedures due to their low risk of prostate cancer.

As the understanding of PSA levels and their implications grows, this research could encourage doctors to reassess screening practices and possibly reduce unnecessary anxiety or procedures for men who fall within the low-risk category. Such approaches may lead to more personalized medical care in the future, potentially minimizing overtreatment while still ensuring that high-risk patients receive necessary attention and interventions.